Author

P. Halfmann

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 5 Immunology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 9 Research Focus:host-pathogen & immune response· 7 Organism:human· 5 Organism:mouse· 3 Assay:proteomics· 3 Research Focus:cell type annotation· 2 Research Focus:drug response / drug discovery· 2 Organism:rat· 2

Frequent Co-Authors

Y. Kawaoka· 8 shared L. A. VanBlargan· 2 shared M. Diamond· 2 shared M. Suthar· 2 shared A. Balaram· 1 shared A. Barkhymer· 1 shared A. Boon· 1 shared A. Ceschi· 1 shared

Activity by Year

2020-2024 · peak 5/yr

Co-Author Collaboration Network

10 top collaborators · 16 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

8 shared papersMicrobiology

Y. Kawaoka

Mutual co-authors in cluster

Author profile →

9 papers

Recent·Most cited

A broadly-neutralizing antibody against Ebolavirus glycoprotein that potentiates the breadth and neutralization potency of other antibodies

F. R. Donnellan, V. Rayaprolu, P. Rijal, V. O'Dowd, A. Parvate, H. Callaway, C. Hariharan, D. Parekh, S. Hui, K. Shaffer, R. Diaz Avalos, K. Hastie, L. Schimanski, H. Müller-Kräuter, T. Strecker, , S. J. Draper

The paper identifies two broadly neutralizing antibodies against Ebolavirus glycoprotein and shows that one enhances the neutralization breadth and potency of other antibodies.

bioRxiv · Jun 21, 2024Immunology

Reduced Pathogenicity of the SARS-CoV-2 Omicron Variant in Hamsters

K. McMahan, V. Giffin, L. Tostanoski, B. Chung, M. Siamatu, M. Suthar, P. Halfmann, Y. Kawaoka, C. Piedra-Mora, A. Martinot, S. Kar, H. Andersen, M. G. Lewis, D. H. Barouch

This study shows the SARS-CoV-2 Omicron variant causes less weight loss in hamsters than previous variants, suggesting reduced lower respiratory tract disease severity.

bioRxiv · Jan 2, 2022Microbiology

mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2

T. L. Darling, B. Ying, B. Whitener, L. VanBlargan, T. L. Bricker, C.-Y. Liang, A. Joshi, G. Bamunuarachchi, K. Seehra, A. Schmitz, P. Halfmann, Y. Kawaoka, S. Elbashir, D. K. Edwards, L. Thackray, , A. Boon

This study evaluates the efficacy of mRNA-1273 and Ad26.COV2.S vaccines against the B.1.621 variant in mice and hamsters, showing protection against infection and pathology.

bioRxiv · Dec 29, 2021Microbiology

An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by several therapeutic monoclonal antibodies

L. A. VanBlargan, J. M. Errico, P. Halfmann, S. J. Zost, J. E. Crowe, L. A. Purcell, Y. Kawaoka, D. Corti, D. H. Fremont, M. Diamond

This study evaluates the neutralization of the SARS-CoV-2 Omicron variant by therapeutic monoclonal antibodies and finds that several lose efficacy against the variant.

bioRxiv · Dec 15, 2021Microbiology

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift

E. Cameroni, C. Saliba, J. E. Bowen, L. E. Rosen, K. Culap, D. Pinto, L. A. VanBlargan, A. De Marco, S. K. Zepeda, J. di Iulio, F. Zatta, H. Kaiser, J. Noack, N. Farhat, N. Czudnochowski, , P

This study shows that Omicron variant's spike protein has enhanced ACE2 binding and reduces neutralizing activity, but some broadly neutralizing antibodies remain effective.

bioRxiv · Dec 12, 2021Immunology

Durability of immune responses to the BNT162b2 mRNA vaccine

M. Suthar, P. S Arunachalam, M. Hu, N. Reis, M. Trisal, O. Raeber, S. Chinthrajah, M. E. Davis-Gardner, K. Manning, P. Mudvari, S. Godbole, E. Boritz, A. R. Henry, D. Douek, K. Nadeau, , P. Halfmann

This study shows that antibody and T cell responses to the BNT162b2 vaccine wane significantly at 6 months, suggesting a potential need for a third booster dose.

bioRxiv · Sep 30, 2021Immunology

Highly efficient SARS-CoV-2 infection of human cardiomyocytes: spike protein-mediated cell fusion and its inhibition

C. K. Navaratnarajah, D. R. Pease, P. Halfmann, B. Taye, A. Barkhymer, K. G. Howell, J. E. Charlesworth, T. A. Christensen, Y. Kawaoka, R. Cattaneo, J. W. Schneider, Boyd Rasmussen and Frank J. Secreto, Timothy J. Nelson (Director)

This paper shows SARS-CoV-2 efficiently infects human cardiomyocytes via spike protein-mediated fusion, which is inhibited by furin blockade.

bioRxiv · Jul 30, 2021Microbiology

SARS-CoV-2 D614G Variant Exhibits Enhanced Replication ex vivo and Earlier Transmission in vivo

Y. J. Hou, S. Chiba, P. Halfmann, C. Ehre, M. Kuroda, K. H. Dinnon, S. R. Leist, A. Schäfer, N. Nakajima, K. Takahashi, R. E. Lee, T. M. Mascenik, C. E. Edwards, L. V. Tse, R. C. Boucher, , R. S. Baric

This study shows the SARS-CoV-2 D614G variant replicates more efficiently and transmits faster in hamsters than the wildtype virus.

bioRxiv · Sep 28, 2020Microbiology

SARS-CoV-2 infection severity is linked to superior humoral immunity against the spike

J. J. Guthmiller, O. Stovicek, J. Wang, S. Changrob, L. Li, P. Halfmann, N.-Y. Zheng, H. Utset, C. T. Stamper, H. L. Dugan, W. D. Miller, M. Huang, Y.-N. Dai, C. A. Nelson, P. D. Hall, , P. C. Wilson

This study finds that severe SARS-CoV-2 infection is associated with stronger antibody and memory B cell responses against the spike protein and nucleocapsid protein.

bioRxiv · Sep 12, 2020Immunology